---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037346"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:55:39.816535+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q3 net loss $50.9M; workforce cut 25%; cash runway to 2027

## Summary
- Net loss $50.9M vs $70.3M YoY; non-GAAP net loss $43.0M (flat YoY).
- Cash, equivalents and securities $598.2M; company expects funding operations into 2027.
- Workforce reduction ~25%; CMO Tina Albertson departing; focus on clinical candidates LYL797 and LYL845.
- Initial clinical data for LYL797 in 1H2024; LYL845 data in 2024; LYL119 IND expected 1H2024.
- R&D expenses $43.8M (+5% YoY); G&A $15.5M (-41% YoY); no revenue.

## SEC filing metadata
- accession: 0001628280-23-037346
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/lyel-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037346
- JSON: https://secwatch.observer/filing/0001628280-23-037346.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037346.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the third quarter ended September 30, 2023 results: revenue approximately zero, net income $50.9 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: approximately zero
  - Net income: $50.9 million
  - Result: reported results
  source text: Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.